Blood Pressure最新文献

英文中文

The INTERSALT Study and the complex relationship between salt intake and blood pressure INTERSALT研究及其与血压的复杂关系

IF 1.8 4区医学 Q3 Medicine

Blood Pressure

Pub Date : 2017-01-04 DOI: 10.1080/08037051.2016.1274957

S. Kjeldsen, K. Narkiewicz, M. Burnier, S. Oparil

The Global Burden of Disease Study 2015 [1] reported that the five largest contributors to global disability-adjusted life years (DALYs) among diseases, injuries and risk factors were high systolic...

2015年全球疾病负担研究[1]报告称，在疾病、损伤和风险因素中，造成全球残疾调整生命年(DALYs)最大的五个因素是高收缩压…

引用次数: 3

The Global Burden of Disease Study 2015 and Blood Pressure 2015年全球疾病负担研究与血压

IF 1.8 4区医学 Q3 Medicine

Blood Pressure

Pub Date : 2017-01-02 DOI: 10.1080/08037051.2016.1267557

S. Kjeldsen, K. Narkiewicz, M. Burnier, S. Oparil

The Global Burden of Disease Study 2015[1] reported that the five largest contributors to global disability-adjusted life-years (DALYs) among diseases, injuries and risk factors were high systolic blood pressure (212 million with 95% Confidence Intervals (CIs) 193–231 million), smoking (149 with 95% CIs 134–163 million), high fasting plasma glucose (143 with 95% CIs 125–164 million), high body mass index (120 million with 95% CIs 84–158 million) and childhood undernutrition (113 million with 95% CIs 104–123 million). High total cholesterol, alcohol use and diets high in sodium were also listed among the top 10 risk factors. Interestingly, in 1990, childhood undernutrition, unsafe water and high systolic blood pressure were the three leading risk factors for attributable DALYs. Of these, only high systolic blood pressure continued to be ranked among the three leading risk factors in 2015. The Global Burden of Disease report concludes that achievement of optimal blood pressure in the population would yield large potential gains in global health and that study of blood pressure in people younger than 60 years of age is an important area for future investigation. A wide array of clinical and population strategies are available to reduce systolic blood pressure, including improving nutrition, increasing physical activity, reducing or slowing the rise of high body mass index, and in many countries providing access to effective anti-hypertensive medications. We believe that the Global Burden of Disease Study is the most useful global effort to inform governments, health care providers and the population at large of the real issues of risk factors, diseases and injuries in the world and the most important global study to reveal that hypertension has remained the leading risk factor for disease and death worldwide for the past quarter century. Blood Pressure is making an important contribution for elucidating the global problem of hypertension by publishing a wide array of research from around the world, as reflected by the papers in the current issue. Disclosure statement

2015年全球疾病负担研究[1]报告称，在疾病、损伤和风险因素中，全球残疾调整后寿命（DALYs）的五个最大因素是收缩压高（2.12亿，95%置信区间1.93-2.31亿）、吸烟（149，95%可信区间1.34-1.63亿）、空腹血糖高（143，高体重指数（1.2亿，95%CI 8.4-1.58亿）和儿童营养不良（1.13亿，95%CI1.04-12.3亿）。高总胆固醇、饮酒和高钠饮食也被列为十大风险因素。有趣的是，1990年，儿童营养不良、饮水不安全和收缩压高是可归因DALY的三个主要风险因素。在这些因素中，只有高收缩压在2015年继续被列为三大主要风险因素。《全球疾病负担报告》得出结论，在人群中实现最佳血压将为全球健康带来巨大的潜在收益，对60岁以下人群血压的研究是未来调查的一个重要领域。有一系列广泛的临床和人群策略可用于降低收缩压，包括改善营养、增加体力活动、减少或减缓高体重指数的上升，以及在许多国家提供有效的抗高血压药物。我们认为，全球疾病负担研究是向各国政府、医疗保健提供者和广大民众通报世界上风险因素、疾病和伤害的真实问题的最有用的全球努力，也是揭示高血压在过去25年中仍然是全球疾病和死亡的主要风险因素的最重要的全球研究。正如本期论文所反映的那样，通过发表来自世界各地的广泛研究，血压为阐明全球高血压问题做出了重要贡献。披露声明

{"title":"The Global Burden of Disease Study 2015 and Blood Pressure","authors":"S. Kjeldsen, K. Narkiewicz, M. Burnier, S. Oparil","doi":"10.1080/08037051.2016.1267557","DOIUrl":"https://doi.org/10.1080/08037051.2016.1267557","url":null,"abstract":"The Global Burden of Disease Study 2015[1] reported that the five largest contributors to global disability-adjusted life-years (DALYs) among diseases, injuries and risk factors were high systolic blood pressure (212 million with 95% Confidence Intervals (CIs) 193–231 million), smoking (149 with 95% CIs 134–163 million), high fasting plasma glucose (143 with 95% CIs 125–164 million), high body mass index (120 million with 95% CIs 84–158 million) and childhood undernutrition (113 million with 95% CIs 104–123 million). High total cholesterol, alcohol use and diets high in sodium were also listed among the top 10 risk factors. Interestingly, in 1990, childhood undernutrition, unsafe water and high systolic blood pressure were the three leading risk factors for attributable DALYs. Of these, only high systolic blood pressure continued to be ranked among the three leading risk factors in 2015. The Global Burden of Disease report concludes that achievement of optimal blood pressure in the population would yield large potential gains in global health and that study of blood pressure in people younger than 60 years of age is an important area for future investigation. A wide array of clinical and population strategies are available to reduce systolic blood pressure, including improving nutrition, increasing physical activity, reducing or slowing the rise of high body mass index, and in many countries providing access to effective anti-hypertensive medications. We believe that the Global Burden of Disease Study is the most useful global effort to inform governments, health care providers and the population at large of the real issues of risk factors, diseases and injuries in the world and the most important global study to reveal that hypertension has remained the leading risk factor for disease and death worldwide for the past quarter century. Blood Pressure is making an important contribution for elucidating the global problem of hypertension by publishing a wide array of research from around the world, as reflected by the papers in the current issue. Disclosure statement","PeriodicalId":55591,"journal":{"name":"Blood Pressure","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2017-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/08037051.2016.1267557","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44531966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 15

Factors associated with diagnostic discrepancy for left ventricular hypertrophy between electrocardiography and echocardiography 心电图和超声心动图诊断左心室肥厚差异的相关因素

IF 1.8 4区医学 Q3 Medicine

Blood Pressure

Pub Date : 2017-01-02 DOI: 10.1080/08037051.2016.1235959

Søren Sandager Petersen, Line Reinholdt Pedersen, M. Pareek, M. L. Nielsen, S. Diederichsen, M. Leósdóttir, P. Nilsson, A. Diederichsen, M. Olsen

Abstract Objective: To investigate the influence of cardiovascular risk factors, including fasting plasma glucose (FPG), on the association between electrocardiographic (ECG) and echocardiographic left ventricular hypertrophy (LVH) in an elderly population. Methods: We tested cross-sectional associations between electrocardiographic and echocardiographic LVH, defining LVH according to the Sokolow-Lyon voltage combination, Cornell voltage-duration product, or left ventricular mass index (LVMI). Differences between standardized LVMI and Sokolow-Lyon voltage combination or Cornell voltage-duration product (absolute value/cut-off value for LVH) were used as outcome variables in order to identify explanatory variables associated with diagnostic discrepancies between ECG and echocardiography. Results: Of the 1382 subjects included, 77% did not display any signs of LVH, 6% had LVH defined by ECG only, 13% had LVH defined by echocardiography only, and 5% had LVH on both ECG and echocardiography. Older subjects and those with higher blood pressure and RWT were more likely to have a relatively greater LVMI on echocardiography than that predicted on ECG (odds ratio: 1.65 per 10 years (95% confidence interval (CI): 1.27-2.15), p = .0002, odds ratio: 1.17 per 10 mmHg (95% CI: 1.09-1.25), p < .0001, and odds ratio: 1.21 per 0.10 (95% CI: 1.02-1.42), p = .03). In addition, discrepancy was also seen in females and subjects receiving antihypertensive medication (odds ratio: 1.41 (95% CI: 1.04-1.89), p = .03 and odds ratio: 1.41 (95% CI: 1.06-1.87), p = .02), but FPG did not independently influence discrepancy between ECG and echocardiography. Conclusion: Age, blood pressure, female sex, greater RWT and use of antihypertensive medication were associated with a greater risk of non-consistency between LVH determined by ECG and echocardiography.

摘要目的：探讨包括空腹血糖（FPG）在内的心血管危险因素对老年人群心电图（ECG）和超声心动图左心室肥大（LVH）相关性的影响。方法：我们测试了心电图和超声心动图LVH之间的横断面相关性，根据Sokolow-Lyon电压组合、Cornell电压持续时间乘积或左心室质量指数（LVMI）定义LVH。标准化LVMI和Sokolow-Lyon电压组合或Cornell电压持续时间乘积之间的差异（LVH的绝对值/截止值）被用作结果变量，以确定与心电图和超声心动图之间的诊断差异相关的解释变量。结果：在纳入的1382名受试者中，77%的受试者没有表现出任何LVH迹象，6%的人仅通过心电图确定LVH，13%的人仅由超声心动图确定LVH；5%的人在心电图和超声心动图上都有LVH。老年受试者和血压和RWT较高的受试者在超声心动图上的LVMI比在心电图上预测的LVMI相对更大（比值比：1.65/10年（95%置信区间（CI）：1.27-2.15），p = .0002，比值比：1.17/10mmHg（95%置信区间：1.09-1.25），p < .0001，比值比：1.21/0.10（95%可信区间：1.02-1.42），p = .03）。此外，女性和接受降压药物治疗的受试者也存在差异（比值比：1.41（95%可信区间：1.04-1.89），p = .比值比：1.41（95%可信区间：1.06-1.87），p = .02），但FPG并不独立影响心电图和超声心动图之间的差异。结论：年龄、血压、女性、较大的RWT和抗高血压药物的使用与心电图和超声心动图测定的LVH不一致的风险较大相关。

{"title":"Factors associated with diagnostic discrepancy for left ventricular hypertrophy between electrocardiography and echocardiography","authors":"Søren Sandager Petersen, Line Reinholdt Pedersen, M. Pareek, M. L. Nielsen, S. Diederichsen, M. Leósdóttir, P. Nilsson, A. Diederichsen, M. Olsen","doi":"10.1080/08037051.2016.1235959","DOIUrl":"https://doi.org/10.1080/08037051.2016.1235959","url":null,"abstract":"Abstract Objective: To investigate the influence of cardiovascular risk factors, including fasting plasma glucose (FPG), on the association between electrocardiographic (ECG) and echocardiographic left ventricular hypertrophy (LVH) in an elderly population. Methods: We tested cross-sectional associations between electrocardiographic and echocardiographic LVH, defining LVH according to the Sokolow-Lyon voltage combination, Cornell voltage-duration product, or left ventricular mass index (LVMI). Differences between standardized LVMI and Sokolow-Lyon voltage combination or Cornell voltage-duration product (absolute value/cut-off value for LVH) were used as outcome variables in order to identify explanatory variables associated with diagnostic discrepancies between ECG and echocardiography. Results: Of the 1382 subjects included, 77% did not display any signs of LVH, 6% had LVH defined by ECG only, 13% had LVH defined by echocardiography only, and 5% had LVH on both ECG and echocardiography. Older subjects and those with higher blood pressure and RWT were more likely to have a relatively greater LVMI on echocardiography than that predicted on ECG (odds ratio: 1.65 per 10 years (95% confidence interval (CI): 1.27-2.15), p = .0002, odds ratio: 1.17 per 10 mmHg (95% CI: 1.09-1.25), p < .0001, and odds ratio: 1.21 per 0.10 (95% CI: 1.02-1.42), p = .03). In addition, discrepancy was also seen in females and subjects receiving antihypertensive medication (odds ratio: 1.41 (95% CI: 1.04-1.89), p = .03 and odds ratio: 1.41 (95% CI: 1.06-1.87), p = .02), but FPG did not independently influence discrepancy between ECG and echocardiography. Conclusion: Age, blood pressure, female sex, greater RWT and use of antihypertensive medication were associated with a greater risk of non-consistency between LVH determined by ECG and echocardiography.","PeriodicalId":55591,"journal":{"name":"Blood Pressure","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2017-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/08037051.2016.1235959","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44673242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Erratum 勘误表

IF 1.8 4区医学 Q3 Medicine

Blood Pressure

Pub Date : 2017-01-02 DOI: 10.1080/08037051.2016.1243366

引用次数: 0

Corrigendum 勘误表

IF 1.8 4区医学 Q3 Medicine

Blood Pressure

Pub Date : 2017-01-02 DOI: 10.1080/14017431.2016.1256051

引用次数: 0

Relationship of diastolic function to new or persistent electrocardiographic left ventricular hypertrophy. 舒张功能与新发或持续性左室肥厚的关系。

IF 1.8 4区医学 Q3 Medicine

Blood Pressure

Pub Date : 2016-12-01 Epub Date: 2016-05-05 DOI: 10.1080/08037051.2016.1179514

Michael T Tanoue, Sverre E Kjeldsen, Richard B Devereux, Peter M Okin

Background: Persistence or development of Cornell product left ventricular hypertrophy (LVH) is associated with increased heart failure (HF) risk that is partly explained by greater LV systolic dysfunction. However, whether new or persistent Cornell product LVH during antihypertensive treatment is associated with worse LV diastolic function is unclear.

Methods: Left ventricular diastolic function was examined in relation to year-3 ECG LVH in 377 hypertensive patients with a preserved LV ejection fraction (>45%) at year-3. Cornell product >2440 mm·ms defined ECG LVH.

Results: In multivariate models adjusting for age, sex, change from baseline to year-3 systolic blood pressure, and baseline and change from baseline to year-3 Sokolow-Lyon voltage, persistent or new Cornell product LVH at year-3 remained associated with year-3 abnormal half filling time (OR 1.63, 95% CI 1.04-2.55 p = 0.034), with a trend toward higher odds of abnormal third filling time (OR 1.51, 95% CI 0.087 p = 0.087) and total filling time (OR 1.79, CI 0.98-3.27 p = 0.059).

Conclusion: In hypertensive patients undergoing antihypertensive therapy, persistence or development of Cornell product ECG LVH at year-3 follow-up is modestly associated with LV diastolic dysfunction. These findings suggest that diastolic dysfunction may be a mechanism via which changing ECG LVH influences HF risk.

背景:Cornell产品左心室肥厚(LVH)的持续或发展与心力衰竭(HF)的风险增加有关，这在一定程度上可以解释为左室收缩功能障碍加重。然而，在降压治疗期间，新的或持续的Cornell产品LVH是否与左室舒张功能恶化有关尚不清楚。方法:对377例左室射血分数保存(>45%)的高血压患者进行左室舒张功能与第3年心电图LVH的关系分析。Cornell产品>2440 mm·ms定义ECG LVH。结果:在调整了年龄、性别、基线至第3年收缩压变化、基线及基线至第3年Sokolow-Lyon电压变化的多变量模型中，第3年的持续或新Cornell产品LVH与第3年异常半填充时间(or 1.63, 95% CI 1.04-2.55 p = 0.034)相关，第三次填充时间(or 1.51, 95% CI 0.087 p = 0.087)和总填充时间(or 1.79, CI 0.98-3.27 p = 0.059)异常的几率更高。结论:在接受降压治疗的高血压患者中，第3年随访时持续或发展的Cornell产品ECG LVH与左室舒张功能障碍有中度相关性。这些发现表明，舒张功能障碍可能是改变ECG LVH影响HF风险的一个机制。

{"title":"Relationship of diastolic function to new or persistent electrocardiographic left ventricular hypertrophy.","authors":"Michael T Tanoue, Sverre E Kjeldsen, Richard B Devereux, Peter M Okin","doi":"10.1080/08037051.2016.1179514","DOIUrl":"https://doi.org/10.1080/08037051.2016.1179514","url":null,"abstract":"Background: Persistence or development of Cornell product left ventricular hypertrophy (LVH) is associated with increased heart failure (HF) risk that is partly explained by greater LV systolic dysfunction. However, whether new or persistent Cornell product LVH during antihypertensive treatment is associated with worse LV diastolic function is unclear.Methods: Left ventricular diastolic function was examined in relation to year-3 ECG LVH in 377 hypertensive patients with a preserved LV ejection fraction (>45%) at year-3. Cornell product >2440 mm·ms defined ECG LVH.Results: In multivariate models adjusting for age, sex, change from baseline to year-3 systolic blood pressure, and baseline and change from baseline to year-3 Sokolow-Lyon voltage, persistent or new Cornell product LVH at year-3 remained associated with year-3 abnormal half filling time (OR 1.63, 95% CI 1.04-2.55 p = 0.034), with a trend toward higher odds of abnormal third filling time (OR 1.51, 95% CI 0.087 p = 0.087) and total filling time (OR 1.79, CI 0.98-3.27 p = 0.059).Conclusion: In hypertensive patients undergoing antihypertensive therapy, persistence or development of Cornell product ECG LVH at year-3 follow-up is modestly associated with LV diastolic dysfunction. These findings suggest that diastolic dysfunction may be a mechanism via which changing ECG LVH influences HF risk.","PeriodicalId":55591,"journal":{"name":"Blood Pressure","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/08037051.2016.1179514","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34454492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Hypertension is strongly associated with false-positive bicycle exercise stress echocardiography testing results. 高血压与自行车运动应激超声心动图检测结果假阳性密切相关。

IF 1.8 4区医学 Q3 Medicine

Blood Pressure

Pub Date : 2016-12-01 Epub Date: 2016-05-10 DOI: 10.1080/08037051.2016.1182419

Karsten Keller, Kathrin Stelzer, Thomas Munzel, Mir Abolfazl Ostad

Introduction: Exercise echocardiography is a reliable routine test in patients with known or suspected coronary artery disease. However, in ∼15% of all patients, stress echocardiography leads to false-positive stress echocardiography results. We aimed to investigate the impact of hypertension on stress echocardiographic results.

Methods: We performed a retrospective study of patients with suspected or known stable coronary artery disease who underwent a bicycle exercise stress echocardiography. Patients with false-positive stress results were compared with those with appropriate results.

Results: 126 patients with suspected or known coronary artery disease were included in this retrospective study. 23 patients showed false-positive stress echocardiography results. Beside comparable age, gender distribution and coronary artery status, hypertension was more prevalent in patients with false-positive stress results (95.7% vs. 67.0%, p = 0.0410). Exercise peak load revealed a borderline-significance with lower loads in patients with false-positive results (100.0 (IQR 75.0/137.5) vs. 125.0 (100.0/150.0) W, p = 0.0601). Patients with false-positive stress results showed higher systolic (2.05 ± 0.69 vs. 1.67 ± 0.39 mmHg/W, p = 0.0193) and diastolic (1.03 ± 0.38 vs. 0.80 ± 0.28 mmHg/W, p = 0.0165) peak blood pressure (BP) per wattage. In a multivariate logistic regression test, hypertension (OR 17.6 [CI 95% 1.9-162.2], p = 0.0115), and systolic (OR 4.12 [1.56-10.89], p = 0.00430) and diastolic (OR 13.74 [2.46-76.83], p = 0.00285) peak BP per wattage, were associated with false-positive exercise results. ROC analysis for systolic and diastolic peak BP levels per wattage showed optimal cut-off values of 1.935mmHg/W and 0.823mmHg/W, indicating false-positive exercise echocardiographic results with AUCs of 0.660 and 0.664, respectively.

Conclusions: Hypertension is a risk factor for false-positive stress exercise echocardiographic results in patients with known or suspected coronary artery disease. Presence of hypertension was associated with 17.6-fold elevated risk of false-positive results.

运动超声心动图是已知或疑似冠状动脉疾病患者的可靠常规检查。然而，在约15%的患者中，应激超声心动图导致假阳性的应激超声心动图结果。我们的目的是研究高血压对应激超声心动图结果的影响。方法:我们对疑似或已知的稳定型冠状动脉疾病患者进行了回顾性研究，这些患者接受了自行车运动应激超声心动图检查。将假阳性应激结果患者与正常应激结果患者进行比较。结果:126例疑似或已知冠状动脉疾病的患者纳入本回顾性研究。23例患者出现应激性超声心动图假阳性。除了具有可比性的年龄、性别分布和冠状动脉状态外，高血压在假阳性应激结果患者中更为普遍(95.7%比67.0%，p = 0.0410)。假阳性结果患者的运动峰值负荷较低，显示出临界显著性(100.0 (IQR 75.0/137.5) vs 125.0 (100.0/150.0) W, p = 0.0601)。假阳性患者的收缩压峰值(2.05±0.69 vs. 1.67±0.39 mmHg/W, p = 0.0193)和舒张压峰值(1.03±0.38 vs. 0.80±0.28 mmHg/W, p = 0.0165)均较高。在多因素logistic回归检验中，高血压(OR 17.6 [CI 95% 1.9-162.2]， p = 0.0115)、收缩压(OR 4.12 [1.56-10.89]， p = 0.00430)和舒张压(OR 13.74 [2.46-76.83]， p = 0.00285)峰值血压/瓦数与假阳性运动结果相关。对每瓦收缩期和舒张期峰值血压水平进行ROC分析，最佳临界值分别为1.935mmHg/W和0.823mmHg/W，表明运动超声心动图结果为假阳性，auc分别为0.660和0.664。结论:高血压是已知或疑似冠状动脉疾病患者应激运动超声结果假阳性的危险因素。存在高血压与假阳性结果的风险增加17.6倍相关。

{"title":"Hypertension is strongly associated with false-positive bicycle exercise stress echocardiography testing results.","authors":"Karsten Keller, Kathrin Stelzer, Thomas Munzel, Mir Abolfazl Ostad","doi":"10.1080/08037051.2016.1182419","DOIUrl":"https://doi.org/10.1080/08037051.2016.1182419","url":null,"abstract":"Introduction: Exercise echocardiography is a reliable routine test in patients with known or suspected coronary artery disease. However, in ∼15% of all patients, stress echocardiography leads to false-positive stress echocardiography results. We aimed to investigate the impact of hypertension on stress echocardiographic results.Methods: We performed a retrospective study of patients with suspected or known stable coronary artery disease who underwent a bicycle exercise stress echocardiography. Patients with false-positive stress results were compared with those with appropriate results.Results: 126 patients with suspected or known coronary artery disease were included in this retrospective study. 23 patients showed false-positive stress echocardiography results. Beside comparable age, gender distribution and coronary artery status, hypertension was more prevalent in patients with false-positive stress results (95.7% vs. 67.0%, p = 0.0410). Exercise peak load revealed a borderline-significance with lower loads in patients with false-positive results (100.0 (IQR 75.0/137.5) vs. 125.0 (100.0/150.0) W, p = 0.0601). Patients with false-positive stress results showed higher systolic (2.05 ± 0.69 vs. 1.67 ± 0.39 mmHg/W, p = 0.0193) and diastolic (1.03 ± 0.38 vs. 0.80 ± 0.28 mmHg/W, p = 0.0165) peak blood pressure (BP) per wattage. In a multivariate logistic regression test, hypertension (OR 17.6 [CI 95% 1.9-162.2], p = 0.0115), and systolic (OR 4.12 [1.56-10.89], p = 0.00430) and diastolic (OR 13.74 [2.46-76.83], p = 0.00285) peak BP per wattage, were associated with false-positive exercise results. ROC analysis for systolic and diastolic peak BP levels per wattage showed optimal cut-off values of 1.935mmHg/W and 0.823mmHg/W, indicating false-positive exercise echocardiographic results with AUCs of 0.660 and 0.664, respectively.Conclusions: Hypertension is a risk factor for false-positive stress exercise echocardiographic results in patients with known or suspected coronary artery disease. Presence of hypertension was associated with 17.6-fold elevated risk of false-positive results.","PeriodicalId":55591,"journal":{"name":"Blood Pressure","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/08037051.2016.1182419","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34470562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

The effect of social class on the amount of salt intake in patients with hypertension. 社会阶层对高血压患者盐摄入量的影响。

IF 1.8 4区医学 Q3 Medicine

Blood Pressure

Pub Date : 2016-12-01 Epub Date: 2016-05-05 DOI: 10.1080/08037051.2016.1179508

Seyed Saeed Mazloomy Mahmoodabad, Hadi Tehrani, Mahdi Gholian-Aval, Hasan Gholami, Mohsen Nematy

Reducing salt intake is a factor related to life style which can influence the prevention of blood pressure. This study was conducted to assess the impact of social class on the amount of salt intake in patients with hypertension in Iran. This was an observational on the intake of salt, as estimated by Kawasaki formula in a sample from Iranian population, stratified for social background characteristics. The finding in general was that the estimated salt intake was somewhat higher in subjects from a lower social background, while the opposite was true for lipid levels (LDL and HDL cholesterol). There was also a significant correlation between salt intake and the level of systolic blood pressure, but not the level of diastolic blood pressure. Considering high salt intake (almost double the standard amount in Iran), especially in patients with low-social class and the effects of salt on human health, it is suggested to design and perform suitable educational programs based on theories and models of health education in order to reduce salt intake.

减少盐的摄入量是一个与生活方式相关的因素，可以影响血压的预防。本研究旨在评估社会阶层对伊朗高血压患者盐摄入量的影响。这是一项关于盐摄入量的观察，根据川崎公式在伊朗人口样本中估计，根据社会背景特征分层。总的来说，研究发现，社会背景较低的受试者的估计盐摄入量略高，而脂质水平(低密度脂蛋白和高密度脂蛋白胆固醇)则相反。盐摄入量与收缩压水平之间也有显著的相关性，但与舒张压水平无关。考虑到伊朗的高盐摄取量(几乎是伊朗标准摄取量的两倍)，特别是社会阶层低的患者，以及盐对人体健康的影响，建议根据健康教育的理论和模型设计和实施适合的教育方案，以减少盐的摄取量。

{"title":"The effect of social class on the amount of salt intake in patients with hypertension.","authors":"Seyed Saeed Mazloomy Mahmoodabad, Hadi Tehrani, Mahdi Gholian-Aval, Hasan Gholami, Mohsen Nematy","doi":"10.1080/08037051.2016.1179508","DOIUrl":"https://doi.org/10.1080/08037051.2016.1179508","url":null,"abstract":"Reducing salt intake is a factor related to life style which can influence the prevention of blood pressure. This study was conducted to assess the impact of social class on the amount of salt intake in patients with hypertension in Iran. This was an observational on the intake of salt, as estimated by Kawasaki formula in a sample from Iranian population, stratified for social background characteristics. The finding in general was that the estimated salt intake was somewhat higher in subjects from a lower social background, while the opposite was true for lipid levels (LDL and HDL cholesterol). There was also a significant correlation between salt intake and the level of systolic blood pressure, but not the level of diastolic blood pressure. Considering high salt intake (almost double the standard amount in Iran), especially in patients with low-social class and the effects of salt on human health, it is suggested to design and perform suitable educational programs based on theories and models of health education in order to reduce salt intake.","PeriodicalId":55591,"journal":{"name":"Blood Pressure","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/08037051.2016.1179508","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34372099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 25

Blood Pressure in 2016: increased impact factor and change of editors. 2016年血压:影响因子增加，编辑变动。

IF 1.8 4区医学 Q3 Medicine

Blood Pressure

Pub Date : 2016-12-01 Epub Date: 2016-09-03 DOI: 10.1080/08037051.2016.1225493

Sverre E Kjeldsen, Krzysztof Narkiewicz, Suzanne Oparil

引用次数: 0

Effect of antihypertensive treatment with lercanidipine on endothelial progenitor cells and inflammation in patients with mild to moderate essential hypertension. 利卡尼地平降压对轻中度原发性高血压患者内皮祖细胞和炎症的影响。

IF 1.8 4区医学 Q3 Medicine

Blood Pressure

Pub Date : 2016-12-01 Epub Date: 2016-05-19 DOI: 10.1080/08037051.2016.1184495

Carolina De Ciuceis, Claudia Rossini, Angela Tincani, Paolo Airò, Mirco Scarsi, Claudia Agabiti-Rosei, Giuseppina Ruggeri, Luigi Caimi, Doris Ricotta, Enrico Agabiti-Rosei, Damiano Rizzoni

Background: It has been demonstrated that circulating endothelial progenitor cells (EPCs) number reflects the endogenous vascular repair ability, with the EPCs pool declining in presence of cardiovascular risk factors. Several drugs, including dihydropyridine calcium channel blockers, have been reported to elicit antioxidant and anti-inflammatory properties, as well as to improve vascular remodeling and dysfunction. However, no data are available about the effects of lercanidipine on EPCs. The aim of the present study was therefore to investigate the effects of short-term treatment with lercanidipine on circulating EPCs, as well as on indices of inflammation and oxidative stress.

Patients and methods: Twenty essential hypertensive patients were included in the study and treated for 4 weeks with lercanidipine 20 mg per day orally. Investigations were performed in basal condition, after appropriate wash out of previous treatments, and after 4 weeks of lercanidipine treatment. Inflammatory and oxidative stress markers were assessed by ELISA technique. Lin-/7AAD-/CD34+/CD133+/VEGFR-2 + and Lin-/7AAD-/CD34+/VEGFR-2 + cells were identified by flow cytometry and considered as EPCs. EPCs cells were expressed as number of cells per million Lin-mononuclear cells.

Results: Circulating EPCs were significantly increased after lercanidipine treatment (CD34+/CD133+/VEGFR-2 + cells: 78.3 ± 64.5 vs 46.6 ± 32.8; CD34+/VEGFR-2+: 87996 ± 165116 vs 1026 ± 1559, respectively, p < 0.05). A modest reduction in circulating indices of inflammation was also observed.

Conclusions: In conclusion, lercanidipine is able to increase the number of circulating EPCs, possibly through a reduction of low-grade inflammation.

背景:研究表明，循环内皮祖细胞(EPCs)数量反映了内源性血管修复能力，当心血管危险因素存在时，EPCs数量会下降。包括二氢吡啶钙通道阻滞剂在内的几种药物已被报道具有抗氧化和抗炎特性，以及改善血管重塑和功能障碍。然而，尚无关于雷卡尼地平对EPCs影响的数据。因此，本研究的目的是研究短期使用来卡尼地平对循环EPCs的影响，以及对炎症和氧化应激指标的影响。患者和方法:选取20例原发性高血压患者，口服雷卡尼地平20mg / d，治疗4周。调查是在基础条件下进行的，在适当洗掉之前的治疗后，在雷卡尼地平治疗4周后。采用ELISA法检测炎症和氧化应激指标。Lin-/7AAD-/CD34+/CD133+/VEGFR-2 +和Lin-/7AAD-/CD34+/VEGFR-2 +细胞经流式细胞术鉴定为EPCs。EPCs细胞以每百万lin -单核细胞的细胞数表示。结果:莱坎地平治疗后循环EPCs显著升高(CD34+/CD133+/VEGFR-2 +细胞:78.3±64.5 vs 46.6±32.8;CD34+/VEGFR-2+:分别为87996±165116和1026±1559,p结论:总之，莱坎地平能够增加循环EPCs的数量，可能是通过减少低级别炎症。

{"title":"Effect of antihypertensive treatment with lercanidipine on endothelial progenitor cells and inflammation in patients with mild to moderate essential hypertension.","authors":"Carolina De Ciuceis, Claudia Rossini, Angela Tincani, Paolo Airò, Mirco Scarsi, Claudia Agabiti-Rosei, Giuseppina Ruggeri, Luigi Caimi, Doris Ricotta, Enrico Agabiti-Rosei, Damiano Rizzoni","doi":"10.1080/08037051.2016.1184495","DOIUrl":"https://doi.org/10.1080/08037051.2016.1184495","url":null,"abstract":"Background: It has been demonstrated that circulating endothelial progenitor cells (EPCs) number reflects the endogenous vascular repair ability, with the EPCs pool declining in presence of cardiovascular risk factors. Several drugs, including dihydropyridine calcium channel blockers, have been reported to elicit antioxidant and anti-inflammatory properties, as well as to improve vascular remodeling and dysfunction. However, no data are available about the effects of lercanidipine on EPCs. The aim of the present study was therefore to investigate the effects of short-term treatment with lercanidipine on circulating EPCs, as well as on indices of inflammation and oxidative stress.Patients and methods: Twenty essential hypertensive patients were included in the study and treated for 4 weeks with lercanidipine 20 mg per day orally. Investigations were performed in basal condition, after appropriate wash out of previous treatments, and after 4 weeks of lercanidipine treatment. Inflammatory and oxidative stress markers were assessed by ELISA technique. Lin-/7AAD-/CD34+/CD133+/VEGFR-2 + and Lin-/7AAD-/CD34+/VEGFR-2 + cells were identified by flow cytometry and considered as EPCs. EPCs cells were expressed as number of cells per million Lin-mononuclear cells.Results: Circulating EPCs were significantly increased after lercanidipine treatment (CD34+/CD133+/VEGFR-2 + cells: 78.3 ± 64.5 vs 46.6 ± 32.8; CD34+/VEGFR-2+: 87996 ± 165116 vs 1026 ± 1559, respectively, p < 0.05). A modest reduction in circulating indices of inflammation was also observed.Conclusions: In conclusion, lercanidipine is able to increase the number of circulating EPCs, possibly through a reduction of low-grade inflammation.","PeriodicalId":55591,"journal":{"name":"Blood Pressure","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/08037051.2016.1184495","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34562387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 16

首页上一页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Blood Pressure

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀